ME Therapeutics is taking advantage of our scientific expertise to  develop IO drugs against novel myeloid cell targets in order to establish a competitive advantage






PhD, Director


PhD, Director



Untitled (3)

Salim Dhanji | PhD, CEO, director, and founder

Dr. Salim Dhanji has been the CEO and a director of ME Therapeutics since September 16, 2014 and is the founder. In addition, he is a member of the Audit Committee. Dr. Dhanji is a former director of preclinical research at Qu Biologics with industry and academic expertise in cancer, autoimmunity and inflammation. Prior to his role at Qu Biologics, Dr. Dhanji was a postdoctoral fellow at the Ontario Cancer Institute where he studied cell signaling pathways involved in autoimmunity and cancer immunity in order to understand how to manipulate the immune system to achieve an anti-cancer immune response. In addition to his experience in biotechnology, Dr. Dhanji is the President of Perceptive Property Development and has served in this role since 2013. Dr. Dhanji obtained a Bachelor of Sciences degree in 2001 and a PhD in Microbiology and Immunology in 2006, both from UBC and has over 20 scientific publications and patents in the areas of cancer, autoimmunity, and inflammation.

Quinn Martin | CPA, CFO

Mr. Quinn Martin is the CFO of ME Therapeutics and is an experienced public company CFO who possesses a CPA designation. Mr. Martin has been a Principal at DBM CPA Inc. since 2018 and was previously a Principal at Davidson & Company LLP. Mr. Martin has extensive experience providing his services as CFO for publicly traded companies. He currently acts as a CFO for five other reporting issuers including Woodbridge Resources Ltd. (Unlisted reporting issuer), Talmine Resources Ltd. (Unlisted reporting issuer), Trifecta Gold Corp. (TSX Venture Exchange), Rhyolite Resources Ltd. (TSX Venture Exchange) and Strategic Metals Ltd. (TSX Venture Exchange). Mr. Martin obtained a Bachelors in Business Administration majoring in Accounting in 2005 from Thompson Rivers University and completed his CPA designation in 2010.

Kenneth Harder | PhD, director

Dr. Kenneth Harder has been a director of the Company since March 9, 2023 and ME Therapeutics since September 16, 2014. Dr. Harder is an Associate Professor in the Dept. of Microbiology and Immunology. He was a Tier2 Canada Research Chair (2007-2018) and Head of UBC’s Infection, Inflammation and Immunity (I3) research group (2015-2022). He completed his PhD in Genetics at UBC in 1996 and post-doctoral studies at the Ludwig Institute for Cancer Research (Melbourne Tumour Biology Branch, 1998-2006).

The Harder lab has pioneered the development of systems biology approaches and genetically engineered mouse models to identify immunological perturbations associated with cancer, obesity, cardiovascular disease, Alzheimer’s disease and intestinal inflammation. Most recently, he has applied approaches such as CyTOF and CITE-seq to the study of lipid nanoparticle (LNP) vaccine design and cancer therapies as a member of the Networks of Centres of Excellence (NCE) Nanomedicine Innovation Network (NMIN). He also studies immune cell adoptive cell therapy for cancer and Alzheimer’s disease. He has trained over 60 students and post-doctoral fellows, and has served on more than 50 graduate student committees. His students have gone on to work in industry including at Stem Cell, NanoVation, AbCellera and PopVax. He has published in high-impact journals including Immunity (IF 43.5), Blood (IF 25.7), Circulation Research (IF 23.2), J. Exp. Med. (IF 17.6), and Cancer Research (IF13.2).

John Priatel | PhD, director

Dr. John Priatel has been a director of ME Therapeutics since September 16, 2014 and a director of the Company since March 9, 2023. He is the Chair of the Audit Committee. Dr. Priatel trained at The Biomedical Research Centre (Vancouver) and Howard Hughes Medical Institute at University of California San Diego receiving his Ph.D. in Genetics from The University of British Columbia. During his doctoral work, he pioneered a new technology to ablate genes in vivo (in a living organism) to study their function. With a fellowship awarded from The Canadian Institutes of Health Research, Dr. Priatel investigated the development and regulation of immune responses, publishing two first-authored articles in the top-tiered journal of immunology Immunity. Dr. Priatel was a Senior Scientist at BC Children’s Hospital Research Institute operating an independent research program. Dr Priatel has published more than 45 academic research articles in the fields of immunity, autoimmunity, and cancer immunotherapy and is an Honorary Assistant Professor within the Department of Pathology and Laboratory Medicine at The University of British Columbia.

Karim Nanji | director

Mr. Karim Nanji was has been a director of the Company since June 7, 2023 and is a member of the Audit Committee. Mr. Nanji is an experienced public director and has experience with start-up companies. Mr. Nanji has a background in retails financial services for underbanked, underserved and credit-challenged consumers in Canada, the United States and international markets. Mr. Nanji has over 25 years of experience across start-up, growth, enterprise and Fortune 500 organizations. Mr. Nanji is currently the CEO and a director of Marble Financial Inc., a fin-tech company listed on the CSE. Prior to his current position, Mr. Nanji was VP, Product & Partnerships with Progressa, a consumer finance company from October 2016 until March 2019. Prior thereto, he was VP Product & Technology with Crelogix Acceptance Corporation from February 2015 until October 2016. Mr. Nanji has a Bachelor of Arts in Economics from UBC and a Master of Business Administration in the Management of Technology from Simon Fraser University.